<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="307990">
  <stage>Registered</stage>
  <submitdate>17/06/2009</submitdate>
  <approvaldate>29/06/2009</approvaldate>
  <actrnumber>ACTRN12609000510246</actrnumber>
  <trial_identification>
    <studytitle>A prospective, randomised, open label trial on the effect of metformin on in-vitro fertilisation outcome in women with polycystic ovary syndrome</studytitle>
    <scientifictitle>A prospective, randomised, open label trial on the effect of metformin on livebirth rates in women with polycystic ovary syndrome undergoing in-vitro fertilization</scientifictitle>
    <utrn />
    <trialacronym>Nil</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility</healthcondition>
    <healthcondition>Polycystic ovary syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Metformin with ovarian stimulation to be continued to 12 weeks gestation if pregnant.
500mg per day metformin slow release (xr) oral tablet for 1 week
1000mg of metformin xr for 1 week
1500mg metformin xr for the remainder of the trial. Metformin to be ceased with negative pregnancy test, or the end of the 12th week of pregnancy
Ovarian stimulation involves subcuticular injections of follicle stimulating hormones and a gonadotrophin releasing hormone(GnRH) antagonist as per the IVF Australia Antagonist:superovulation protocol. There are 2 different dose regimes for GnRH and this depends on the doctor. An injection of 250 international units of human chorionic gonadotrophin is given 36 hours prior to egg collection</interventions>
    <comparator>Women with the same condition undergoing an antagonist cycle of in-vitro fertilisation(IVF) who have been randomised to no treatment as opposed to treatment with metformin, ie. no metformin with standard in-virto fertilisation(IVF) treatment.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Livebirth</outcome>
      <timepoint>10 months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Miscarriage rate</outcome>
      <timepoint>16 weeks after randomization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Polycystic ovary syndrome(PCOS)
Infertility
Both ovaries present
Informed Consent to in-vitro fertilisation treatment
Age 20-38years inclusive
Use of an Antagonist cycle</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>38</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Contraindication to metformin
Metformin use in previous month
Previous participation in the trial
Oocyte donor</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The patient is enrolled and then randomised via a central randomisation website</concealment>
    <sequence>Random computer generation</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>124</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Fertility Society of Australia</primarysponsorname>
    <primarysponsoraddress>61 Dank St
Port Melbourne
VIC 3207</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Fertility Society of Australia</fundingname>
      <fundingaddress>61 Dank St
Port Melbourne
VIC 3207</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial aims to assess whether metformin during ivf treatment and in the first trimester of pregnancy increases livebirth rate and reduces miscarriage rate in women with polycystic ovary syndrome.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IVF Australia Ethics Committee</ethicname>
      <ethicaddress>Level 2 /176 Pacific Highway
Greenwich
NSW  2065</ethicaddress>
      <ethicapprovaldate>1/05/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Juliette Koch</name>
      <address>Reproductive Medicine
Royal Hospital for Women
Barker St
Randwick
NSW  2031</address>
      <phone>+61 2 93826666</phone>
      <fax />
      <email>juliette.koch@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Juliette Koch</name>
      <address>Reproductive Medicine
Royal Hospital for Women
Barker St
Randwick  2031
NSW</address>
      <phone>+61 2 93826666</phone>
      <fax />
      <email>juliette.koch@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Juliette Koch</name>
      <address>Reproductive Medicine
Royal Hospital for Women
Barker St
Randwick 2031
NSW</address>
      <phone />
      <fax />
      <email>juliette.koch@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>